TY  - JOUR
AU  - Veljković, Veljko
AU  - Metlaš, Radmila
AU  - Kohler, Heike
AU  - Urnovitz, HB
AU  - Prljić, Jelena
AU  - Veljković, Nevena V.
AU  - Johnson, Emmett
AU  - Muller, S
PY  - 2001
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2419
AB  - Current expansion of AIDS pandemic significantly accelerates AIDS vaccine research resulting in development and clinical testing of several AIDS vaccine candidates. At the same time, available experimental and clinical data demonstrate that current AIDS vaccine strategy is unsuccessful resulting in development of inefficient and harmful vaccines. This overview briefly summarizes reported results which point out the requirement for moratorium on the current clinical trials of HIV-1 gp120/160 vaccines and urgent need for development of a new, efficient and safe AIDS vaccine strategy. (C) 2001 Elsevier Science Ltd. All rights reserved.
T2  - Vaccine
T1  - AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy
VL  - 19
IS  - 15-16
SP  - 1855
EP  - 1862
DO  - 10.1016/S0264-410X(00)00194-8
ER  - 

@article{
author = "Veljković, Veljko and Metlaš, Radmila and Kohler, Heike and Urnovitz, HB and Prljić, Jelena and Veljković, Nevena V. and Johnson, Emmett and Muller, S",
year = "2001",
abstract = "Current expansion of AIDS pandemic significantly accelerates AIDS vaccine research resulting in development and clinical testing of several AIDS vaccine candidates. At the same time, available experimental and clinical data demonstrate that current AIDS vaccine strategy is unsuccessful resulting in development of inefficient and harmful vaccines. This overview briefly summarizes reported results which point out the requirement for moratorium on the current clinical trials of HIV-1 gp120/160 vaccines and urgent need for development of a new, efficient and safe AIDS vaccine strategy. (C) 2001 Elsevier Science Ltd. All rights reserved.",
journal = "Vaccine",
title = "AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy",
volume = "19",
number = "15-16",
pages = "1855-1862",
doi = "10.1016/S0264-410X(00)00194-8"
}

Veljković, V., Metlaš, R., Kohler, H., Urnovitz, H., Prljić, J., Veljković, N. V., Johnson, E.,& Muller, S.. (2001). AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy. in Vaccine, 19(15-16), 1855-1862.
https://doi.org/10.1016/S0264-410X(00)00194-8

Veljković V, Metlaš R, Kohler H, Urnovitz H, Prljić J, Veljković NV, Johnson E, Muller S. AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy. in Vaccine. 2001;19(15-16):1855-1862.
doi:10.1016/S0264-410X(00)00194-8 .

Veljković, Veljko, Metlaš, Radmila, Kohler, Heike, Urnovitz, HB, Prljić, Jelena, Veljković, Nevena V., Johnson, Emmett, Muller, S, "AIDS epidemic at the beginning of the third millennium: time for a new AIDS vaccine strategy" in Vaccine, 19, no. 15-16 (2001):1855-1862,
https://doi.org/10.1016/S0264-410X(00)00194-8 . .

TY  - JOUR
AU  - Prljić, Jelena
AU  - Veljković, Nevena V.
AU  - Doliana, R
AU  - Colombatti, A
AU  - Johnson, Emmett
AU  - Metlaš, Radmila
AU  - Veljković, Veljko
PY  - 1999
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2230
AB  - Because of a sequence similarity between the HIV-1 envelope glycoprotein gp120 and the variable region of human immunoglobulins, we have suggested that the use of this protein as a vaccine component could strongly influence the host immune system, making it more vulnerable to HIV, and in the long term, accelerate disease progression in asymptomatic HIV patients. Using a chimeric primer consisting of the nucleotide sequence derived from the HIV-1 env gene coding for the second conserved region of gp120, and the highly conserved sequence derived from the human immunoglobulin gene coding for the VHIII domain, we have identified in sera of AIDS patients HIV-I field isolates carrying the complete and active Chi recombinational hot spot (GCTGGTGG). We have also demonstrated in vivo recombination between the HIV-I gene coding for the central portion of the gp120 involving the V3 loop and the bacterial gene coding for the clp protease. These results strongly support and reinforce the previous contention and the serious concern that AIDS vaccine candidates carrying the HIV-1 env gene on viral and bacterial vectors, could result in the generation of new pathogens with unpredictable effects on the immune system. (C) 1999 Elsevier Science Ltd. All rights reserved.
T2  - Vaccine
T1  - Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines
VL  - 17
IS  - 11-12
SP  - 1462
EP  - 1467
DO  - 10.1016/S0264-410X(98)00373-9
ER  - 

@article{
author = "Prljić, Jelena and Veljković, Nevena V. and Doliana, R and Colombatti, A and Johnson, Emmett and Metlaš, Radmila and Veljković, Veljko",
year = "1999",
abstract = "Because of a sequence similarity between the HIV-1 envelope glycoprotein gp120 and the variable region of human immunoglobulins, we have suggested that the use of this protein as a vaccine component could strongly influence the host immune system, making it more vulnerable to HIV, and in the long term, accelerate disease progression in asymptomatic HIV patients. Using a chimeric primer consisting of the nucleotide sequence derived from the HIV-1 env gene coding for the second conserved region of gp120, and the highly conserved sequence derived from the human immunoglobulin gene coding for the VHIII domain, we have identified in sera of AIDS patients HIV-I field isolates carrying the complete and active Chi recombinational hot spot (GCTGGTGG). We have also demonstrated in vivo recombination between the HIV-I gene coding for the central portion of the gp120 involving the V3 loop and the bacterial gene coding for the clp protease. These results strongly support and reinforce the previous contention and the serious concern that AIDS vaccine candidates carrying the HIV-1 env gene on viral and bacterial vectors, could result in the generation of new pathogens with unpredictable effects on the immune system. (C) 1999 Elsevier Science Ltd. All rights reserved.",
journal = "Vaccine",
title = "Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines",
volume = "17",
number = "11-12",
pages = "1462-1467",
doi = "10.1016/S0264-410X(98)00373-9"
}

Prljić, J., Veljković, N. V., Doliana, R., Colombatti, A., Johnson, E., Metlaš, R.,& Veljković, V.. (1999). Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines. in Vaccine, 17(11-12), 1462-1467.
https://doi.org/10.1016/S0264-410X(98)00373-9

Prljić J, Veljković NV, Doliana R, Colombatti A, Johnson E, Metlaš R, Veljković V. Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines. in Vaccine. 1999;17(11-12):1462-1467.
doi:10.1016/S0264-410X(98)00373-9 .

Prljić, Jelena, Veljković, Nevena V., Doliana, R, Colombatti, A, Johnson, Emmett, Metlaš, Radmila, Veljković, Veljko, "Identification of an active Chi recombinational hot spot within the HIV-1 envelope gene: consequences for development of AIDS vaccines" in Vaccine, 17, no. 11-12 (1999):1462-1467,
https://doi.org/10.1016/S0264-410X(98)00373-9 . .

TY  - JOUR
AU  - Veljković, Veljko
AU  - Johnson, Emmett
AU  - Metlaš, Radmila
PY  - 1997
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2059
AB  - Molecular bases of possible harmful effects of AIDS vaccine candidates based on HIV-I gp120/160, that are prepared for Phase III clinical trials in developing countries, have been considered. (C) 1997 Elsevier Science Ltd.
T2  - Vaccine
T1  - Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120
VL  - 15
IS  - 5
SP  - 473
EP  - 474
DO  - 10.1016/S0264-410X(97)00011-X
ER  - 

@article{
author = "Veljković, Veljko and Johnson, Emmett and Metlaš, Radmila",
year = "1997",
abstract = "Molecular bases of possible harmful effects of AIDS vaccine candidates based on HIV-I gp120/160, that are prepared for Phase III clinical trials in developing countries, have been considered. (C) 1997 Elsevier Science Ltd.",
journal = "Vaccine",
title = "Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120",
volume = "15",
number = "5",
pages = "473-474",
doi = "10.1016/S0264-410X(97)00011-X"
}

Veljković, V., Johnson, E.,& Metlaš, R.. (1997). Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120. in Vaccine, 15(5), 473-474.
https://doi.org/10.1016/S0264-410X(97)00011-X

Veljković V, Johnson E, Metlaš R. Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120. in Vaccine. 1997;15(5):473-474.
doi:10.1016/S0264-410X(97)00011-X .

Veljković, Veljko, Johnson, Emmett, Metlaš, Radmila, "Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120" in Vaccine, 15, no. 5 (1997):473-474,
https://doi.org/10.1016/S0264-410X(97)00011-X . .